The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

BJU International

Volumn 106, Issue 4, 2010, Pages 506-514

  Cardozo, Linda ^a   Thorpe, Andrew ^b   Warner, Juliet ^c   Sidhu, Manpreet ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c Decision Resources Group   (United Kingdom)

^d ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

antimuscarinic agents; cost effectiveness; overactive bladder; solifenacin

Indexed keywords

ACETYLCHOLINE; DARIFENACIN; FESOTERODINE; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; BENZHYDRYL DERIVATIVE; BENZILIC ACID DERIVATIVE; CRESOL; DELAYED RELEASE FORMULATION; MANDELIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL PRACTICE; CONSULTATION; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GENERAL PRACTITIONER; HUMAN; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; OUTPATIENT CARE; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; UNITED KINGDOM; URINARY FREQUENCY; URINE INCONTINENCE; COMPARATIVE STUDY; DECISION TREE; DELAYED RELEASE FORMULATION; ECONOMICS; QUALITY OF LIFE; URINARY BLADDER, OVERACTIVE;

BENZHYDRYL COMPOUNDS; BENZILATES; COST-BENEFIT ANALYSIS; CRESOLS; DECISION TREES; DELAYED-ACTION PREPARATIONS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUALITY OF LIFE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 77955068287     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09160.x     Document Type: Article

References (30)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 178 (Pubitemid 34195211)
2. Abrams P, Artibani W, Cardozo LD et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009 28 : 287
3. Chapple C, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder syndrome: current concepts and future prospects. BJU Int 2005 95 : 335 40
4. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005 95 : 335 340
5. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006 50 : 1306 1314
6. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 766
7. Reeves P, Irwin D, Kelleher C et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006 50 : 1050 1057
8. Brown JS, Subak LL, Gras J, Brown BA, Kuppermann M, Posner SF. Urge incontinence: the patient's perspective. J Womens Health 1998 7 : 1263 1269
9. Lam GW, Foldspang A, Elving LB, Mommsen S. Social context, social abstention, and problem recognition correlated with adult female urinary incontinence. Dan Med Bull 1992 39 : 565 570
10. Roe B, May C. Incontinence and sexuality: findings from a qualitative perspective. J Adv Nurs 1999 30 : 573 579
11. Simeonova Z, Milsom I, Kullendorff AM, Molander U, Bengtsson C. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet Gynecol Scand 1999 78 : 546 551
12. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality- of-life aspects of urinary urge incontinence. Pharmacoeconomics 1996 9 : 11 23
13. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000 6 (Suppl S580 90
14. Roe B, Doll H, Wilson K. Help seeking behaviour and health and social services utilisation by people suffering from urinary incontinence. Int J Nurs Stud 1999 36 : 245 253
15. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 2003 43 : 1 5
16. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 562
17. Astellas Pharma. Efficacy and tolerability of solifenacin for treatment of overactive bladder. A systematic review and indirect comparison. Data on file 2008
18. IMS Health. Gains vs losses by product form strength. MAT, April 2008
19. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder. The example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998 17 : 599 611
20. Getsios D, Caro JJ, Ishak KJ et al. Oxybutynin extended release and tolterodine immediate release: a health economic comparison. Clin Drug Investig 2004 24 : 81 8
21. Department of Health. National Tariff 2007-2008: Outpatients Tariff. 2006. Available at: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT-ID=4140197&chk=9QeNwB. Accessed October 2008
22. Curtis L. Unit Costs of Health and Social Care 2007.
23. British Medical Association. British National Formulary, no. 56.
24. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006 26 : 1694 1702
25. Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrom J. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand 2009 88 : 693 699
26. Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008 24 : 2173 2179
27. Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Investig 2004 24 : 305 321
28. Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther 2004 26 : 431 438
29. Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Managed Care Interface 2000 13 : 88 94
30. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001 23 : 2038 2049